Aptose Biosciences Inc. Files 8-K on Financials
Ticker: APTOF · Form: 8-K · Filed: Nov 8, 2024 · CIK: 882361
Sentiment: neutral
Topics: financial-condition, operations, filing
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Nov 8th covering financials. Check it for operational updates.
AI Summary
Aptose Biosciences Inc. filed an 8-K on November 8, 2024, reporting on its results of operations and financial condition. The filing details financial statements and exhibits related to the company's business operations. Aptose Biosciences Inc. is incorporated in Canada and operates in the biological products sector.
Why It Matters
This filing provides crucial updates on Aptose Biosciences Inc.'s financial health and operational status, which is important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Aptose Biosciences Inc. is subject to inherent risks associated with drug development, clinical trials, and regulatory approvals, which can significantly impact its financial condition.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- November 8, 2024 (date) — Date of earliest event reported
- Canada (location) — State of incorporation
- Lorus Therapeutics Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Aptose Biosciences Inc.?
The primary purpose of this 8-K filing is to report on Aptose Biosciences Inc.'s results of operations and financial condition, including financial statements and exhibits.
On what date was this 8-K report filed or effective?
The report was filed as of November 8, 2024, and the date of the earliest event reported is also November 8, 2024.
What industry does Aptose Biosciences Inc. operate in?
Aptose Biosciences Inc. operates in the Biological Products (No Diagnostic Substances) sector, with SIC code 2836.
Has Aptose Biosciences Inc. operated under any previous names?
Yes, Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. (name change effective September 5, 2014) and prior to that, Imutec Pharma Inc. (name change effective January 13, 1997).
Where is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-11-08 16:02:10
Filing Documents
- f8k_110824.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 60KB
- 0001171843-24-006175.txt ( ) — 281KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_110824_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 8, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated November 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: November 8, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer